Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#3727 PREF-NET: A patient preference and experience study of lanreotide autogel (LAN) administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the UK

Introduction: The somatostatin analogue LAN is a common first-line treatment for NETs that can be given at home in a ready-to-use syringe every 4 weeks in the UK.

Conference:

Presenting Author: Khan M

Authors: Khan M, Davies L, Back M, Shah T, Pritchard D,

Keywords: patient participation, somatostatin analogues, injections, quality of life, value-based health care,

#3515 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,